Asthma

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1970 times

25 Asthma

Asthma means ‘laboured breathing’ in Greek and was first described 3000 years ago. It is a broad term used to refer to a disorder of the respiratory system that leads to episodic difficulty in breathing. The national UK guidelines (BTS/SIGN, 2009) define asthma as ‘a chronic inflammatory disorder of the airways which occurs in susceptible individuals; inflammatory symptoms are usually associated with widespread but variable airflow obstruction and an increase in airway response to a variety of stimuli. Obstruction is often reversible either spontaneously or with treatment’.

Epidemiology

The exact prevalence of asthma remains uncertain because of the differing ways in which airway restriction is reported, diagnostic uncertainty (especially for children under 2 years) and the overlap with other conditions such as chronic obstructive pulmonary disease (COPD). Over 5 million people in the UK have asthma (Asthma UK, 2001) and around 300 million worldwide. Mortality from asthma is estimated at approximately 0.4 per 100,000 with around 1400 deaths per annum in the UK. Most deaths occur outside hospital; the most common reasons for death are thought to be inadequate assessment of the severity of airway obstruction by the patient and/or clinician and inadequate therapy with inhaled or oral steroids.

The probability of children having asthma-like symptoms is estimated to be between 5% and 12%, with a higher occurrence in boys than girls and in children whose parents have an allergic disorder. Between 30% and 70% of children will become symptom free by adulthood. Individuals who develop asthma at an early age, however, do have a poorer prognosis.

The prevalence of asthma actually appears to be rising despite advances in therapy. There is some doubt about this, however, due to the differing criteria for the diagnosis of asthma used in different studies. Asthma is considered to be one of the consequences of Western civilisation and appears to be related to a number of environmental factors. Air pollution resulting from industrial sources and transport may be interacting with smoking, dietary and other factors to increase the incidence of this debilitating problem.

Aetiology

The two main causes of asthma symptoms are airway hyperresponsiveness and bronchoconstriction. Hyperresponsiveness is an increased tendency of the airway to react to stimuli or triggers to cause an asthma attack. Bronchoconstriction is a narrowing of the airways that causes airflow obstruction. Possible triggers are listed in Table 25.1. One of the most common trigger factors is the allergen found in the faeces of the house dust mite, which is almost universally present in bedding, carpets and soft furnishing. Pollen from grass (prevalent in June and July) can lead to seasonal asthma. The role of occupation in the development of asthma has become apparent with increased industrialisation. There are many causes of occupational asthma, and bronchial reactivity may persist for years after exposure to the trigger factor. Drug-induced asthma can be severe and the most common causes are β-blocker drugs and prostaglandin synthetase inhibitors. The administration of β-adrenoceptor blockers to a patient, even in the form of eye drops, can cause β2-receptor blockade and consequent bronchoconstriction. Selective β-adrenoceptor blockers are thought to pose slightly less risk, but as these lose their selectivity at higher doses, it is generally recommended that this group of drugs is avoided altogether in asthma patients. Aspirin and related non-steroidal anti-inflammatory drugs can cause severe bronchoconstriction in susceptible individuals. Aspirin inhibits the enzyme cyclo-oxygenase, which normally converts arachidonic acid to (bronchodilatory) prostaglandins. When this pathway is blocked, an alternative reaction predominates, leading to an increase in production of bronchoconstrictor (cys-) leukotrienes. Figures from differing studies vary, but between 2% and 20% of the adult asthma population are thought to be sensitive to aspirin.

Table 25.1 Examples of asthma triggers

Trigger Examples
Allergens Pollens, moulds, house dust mite, animals (dander, saliva and urine)
Industrial chemicals Manufacture of, for example, isocyanate-containing paints, epoxy resins, aluminium, hair sprays, penicillins and cimetidine
Drugs Aspirin, ibuprofen and other prostaglandin synthetase inhibitors, β-adrenoceptor blockers
Foods A rare cause but examples include nuts, fish, seafood, dairy products, food colouring, especially tartrazine, benzoic acid and sodium metabisulfite
Environmental pollutants Traffic fumes. cigarette smoke, sulphur dioxide
Other industrial triggers Wood or grain dust, colophony in solder, cotton, dust, grain weevils and mites
Miscellaneous Cold air, exercise, hyperventilation, viral respiratory tract infections, emotion or stress, swimming pool chlorine

Pathophysiology

Asthma can be classified according to the underlying pattern of airway inflammation with the presence or absence of eosinophils in the airways (eosinophilic vs. non-eosinophilic). Traditionally patients are described as having ‘extrinsic asthma’ when an allergen is thought to be the cause of their asthma. This is more common in children with a history of atopy, where triggers, such as dust mite, cause IgE production. Other environmental factors are also important, such as exposure to rhinovirus during the first 3 years of life (Holgate et al., 2010). ‘Intrinsic asthma’ develops in adulthood, with symptoms triggered by non-allergenic factors such as a viral infection, irritants which cause epithelial damage and mucosal inflammation, emotional upset which mediates excess parasympathetic input or exercise which causes water and heat loss from the airways, triggering mediator release from mast cells. In practice, patients often have features of both types of asthma and the classification is unhelpful and oversimplifies the pathogenesis of asthma.

Mast cell components are released as a result of an IgE antibody-mediated reaction on the surface of the cell. Histamine and other mediators of inflammation are released from mast cells, for example, leukotrienes, prostaglandins, bradykinin, adenosine and prostaglandin-generating factor of anaphylaxis, as well as various chemotactic agents that attract eosinophils and neutrophils. Macrophages release prostaglandins, thromboxane and platelet-activating factor (PAF). PAF appears to sustain bronchial hyperreactivity and cause respiratory capillaries to leak plasma, which increases mucosal oedema. PAF also facilitates the accumulation of eosinophils within the airways, a characteristic pathological feature of asthma. Eosinophils release various inflammatory mediators such as leukotriene C4 (LTC4) and PAF. Epithelial damage results and thick viscous mucus is produced that causes further deterioration in lung function. These cell-derived mediators also play a role in causing marked hypertrophy and hyperplasia of bronchial smooth muscle (these structural changes are described as ‘airway remodelling’), mucus gland hypertrophy leading to excessive mucus production and airway plugging, airway oedema, acute bronchoconstriction and impaired mucociliary clearance.

Mucus production is normally a defence mechanism, but in asthma patients, there is an increase in the size of bronchial glands and goblet cells that produce mucus. Mucus transport is dependent on its viscosity. If it is very thick, it plugs the airways, which also become blocked with epithelial and inflammatory cell debris. Mucociliary clearance is also decreased due to inflammation of epithelial cells. The environmental insults causing asthma are also thought to affect the structure and function of the airway epithelium. The exact role of these cytokines, cellular mediators and the interrelationships with each other and with the causative allergenic or non-allergenic mechanisms has, however, yet to be fully determined and may vary over time (Douwes et al., 2002; Holgate et al., 2010). Fig. 25.1 outlines the main cellular mechanisms involved.

Clinical manifestations

Asthma can present in a number of ways. It may manifest as a persistent cough, but most commonly, it is described as recurrent episodes of difficulty in breathing (dyspnoea) associated with wheezing (a high-pitched noise due to turbulent airflow through a narrowed airway). Diagnosis is usually made from the clinical history confirmed by demonstration of reversible airflow obstruction and measures of lung function. The history of an asthma patient often includes the presence of atopy and allergic rhinitis in the close family. Symptoms of asthma are often intermittent, and the frequency and severity of an episode can vary from individual to individual. Between periods of wheezing and breathlessness, patients may feel quite well. The absence of an improvement in ventilation, however, cannot rule out asthma, and in younger children, it is sometimes very difficult to perform lung function tests; in this case, diagnosis relies on subjective symptomatic improvement in response to bronchodilator therapy.

Acute severe asthma is a dangerous condition that requires hospitalisation and immediate emergency treatment. It occurs when bronchospasm has progressed to a state where the patient is breathless at rest and has a degree of cardiac stress. This is usually progressive and can build up over a number of hours or even days. The breathlessness, with a peak flow rate <100 L/min, is so severe that the patient often cannot talk or lie down. Expiration is particularly difficult and prolonged as air is trapped beneath mucosal inflammation. The pulse rate can give an indication of severity; severe acute asthma can increase the pulse rate to more than 110 beats/min in adults. It is common to see hyperexpansion of the thoracic cavity and lowering of the diaphragm, which means that accessory respiratory muscles are required to try to inflate the chest. Breathing can become rapid (>30 breaths/min) and shallow, leading to low oxygen saturation (SpO2 < 92%) with the patient becoming fatigued, cyanosed, confused and lethargic. The arterial carbon dioxide tension (PaCO2) is usually low in acute asthma. If it is high, it should respond quickly to emergency therapy. Hypercapnia (high PaCO2 level) that does not diminish is a more severe problem and indicates progression towards respiratory failure.

Some patients remain difficult to control with persistent symptoms and/or despite treatment at BTS/SIGN step 4 or 5. This is known as ‘refractory’ or ‘difficult to treat’ asthma. These patients must be carefully evaluated by a respiratory specialist; this will include confirming an accurate diagnosis of asthma, adherence to therapy and individual psychological factors.

Investigations

The function of the lungs can be measured to help diagnose and monitor various respiratory diseases. A series of routine tests has been developed to assess asthma as well as other respiratory diseases such as COPD.

The most useful test for abnormalities in airway function is the forced expiratory volume (FEV). This is measured by means of lung function assessment apparatus such as a spirometer. The patient inhales as deeply as possible and then exhales forcefully and completely into a mouthpiece connected to a spirometer. The FEV1 is a measure of the FEV in the first second of exhalation. The forced vital capacity (FVC) can also be measured, which is an assessment of the maximum volume of air exhaled with maximum effort after maximum inspiration. The FEV1 is usually expressed as a percentage of the total volume of air exhaled, reported as the FEV1/FVC ratio. This ratio is a useful and highly reproducible measure of the capabilities of the lungs. Normal individuals can exhale at least 70% of their total capacity in 1 s. In obstructive lung disorders, such as asthma, the FEV1 is usually decreased, the FVC normal or slightly reduced and the FEV1/FVC ratio decreased, usually <0.7 (Fig. 25.2).

A peak flow meter is a useful means of self-assessment for the patient. It gives slightly less reproducible results than the spirometer but has the advantage that the patient can do regular tests at home with a hand-held meter. The peak flow meter measures peak expiratory flow (PEF) rate, the maximum flow rate that can be forced during expiration. The PEF can be used to assess the improvement or deterioration in the disease as well as the effectiveness of treatment. For all three measurements (FEV1, FVC and PEF), there are normal values with which the patient’s results can be compared. However, these normal values vary with age, race, gender, height and weight. The measurement of FEV1, FVC or PEF does not detect early deterioration of lung function such as bronchospasm and mucus plugging in the smaller airways.

The diagnosis of asthma can be confirmed by measuring the response to a bronchodilator or by examining a patient’s day-to-day variation in PEF readings. A diurnal variability of 60 L/min (or more than 20%) is highly suggestive of asthma (GINA, 2009). However, individuals may not have airflow obstruction at the time of the test, so the absence of an improvement does not rule out asthma. In this situation, peak flow readings can be done at home with repeated pre- and post-bronchodilator readings taken at various times of the day.

Treatment

As asthma involves inflammation and bronchoconstriction, treatment should be directed towards reducing inflammation and increasing bronchodilation. Treatment aims should include a lack of day and nighttime symptoms, no asthma exacerbations, no need for rescue medication, normal PEFs and no unwanted side effects from medication (BTS/SIGN, 2009; GINA, 2009). Anti-inflammatory drugs should be given to all but those with the mildest of symptoms. Other measures, such as avoidance of recognised trigger factors, may also contribute to the control of this disease. The lowest effective dose of drugs should be given to minimise short-term and long-term side effects. It should, however, always be remembered that asthma is a potentially life-threatening illness, is often undertreated and not all patients will achieve optimal control. Common therapeutic and practice problems encountered in the management of asthma are outlined in Box 25.1.

Chronic asthma

The pharmacological management of asthma depends upon the frequency and severity of a patient’s symptoms. Infrequent attacks can be managed by treating each attack when it occurs, but with more frequent attacks, preventive therapy needs to be used.

The preferred route of administration of the agents used in the management of asthma is by inhalation. This allows the drugs to be delivered directly to the airways in smaller doses and with fewer side effects than if systemic routes were used. Inhaled bronchodilators also have a faster onset of action than when administered systemically and give better protection from bronchoconstriction.

Treatment of chronic asthma should be managed in a stepwise progression. This section concentrates on management in adults, as outlined in Fig. 25.3, but corresponding management steps for children are available (BTS/SIGN, 2009). Therapy is moved up the steps according to the severity of the patient’s asthma symptoms and response to current treatment. When a patient has been stable for at least 3 months (GINA, 2009), therapy should be stepped back down; for example, by halving the inhaled corticosteroid (ICS) dose. International guidelines aim for management to achieve and maintain clinical control, which is defined in Table 25.2. A model for patient review and adjustment of therapy, based on assessment of asthma control, has been suggested (Crompton et al., 2006) and is shown in Fig. 25.4. To help in patient education, the terms used to describe the effects of asthma medication are similar across all manufacturers and sources of education. ‘Reliever’ is used for agents that give immediate relief of symptoms. Agents that act to reduce inflammation or give long-term bronchodilation are referred to as ‘controllers’ or ‘preventers’.

image

Fig. 25.3 Summary of stepwise management in adults

(reproduced by permission of the BMJ Publishing Group, from BTS/SIGN, 2009).

image

Fig. 25.4 Adjusting therapy to achieve asthma control

(from Crompton et al., 2006 reproduced by permission. Copyright Elsevier publishing).

Reliever medication

Additional bronchodilators

Additional bronchodilators may be required if the above therapy does not adequately control symptoms (Tables 25.3 and 25.4).

Long acting β-adrenoreceptor agonist bronchodilators

When low-dose inhaled steroids fail to control asthma symptoms adequately at step 3, long-acting β2-agonists should be added instead of increasing the steroid dose. Symptom relief after a trial period, for example, 4–6 weeks, must then be assessed to see if the LABA has been effective and whether further treatment needs to be added to or existing treatment changed.

Meta-analysis of LABA trials has shown a potential increase in asthma deaths of 1 death in 1000 patient-years of use, but this increased risk is lessened when used alongside ICSs (Saltpeter et al., 2006). Taking this evidence into account, it is advised that LABAs should

Combination ICS/LABA inhalers are available which may improve adherence compared to separate inhalers; as adherence to ICS is generally poor, using combination inhalers may ensure that the LABA is not used alone for variable periods of time.

A formoterol and budesonide combination inhaler can be given both as maintenance therapy and for symptomatic relief. Current trial evidence shows that this dosing method is an alternative at step 3 for adults who are poorly controlled on SABA and ICS, have experienced one or more severe exacerbations in the previous 12 months, or as an alternative to increasing the ICS dose to above 2 mg/day at step 4 (NPC, 2008).

Oral bronchodilators

Oral bronchodilators can also be added, for example, theophylline at steps 3–4 or β2-agonists at step 4 for additional symptom control. Slow-release forms should be used, usually twice daily, although these can be used in a single night-time dose if nocturnal symptoms are troublesome.

Theophylline should be started at a dose of 400–500 mg/day in adults and, if required, increased after 7 days to 800–1000 mg/day. In children, higher doses may be required but this will be determined by the age of the child (see Chapter 10).

Theophylline has a narrow therapeutic index and its hepatic metabolism varies greatly between individuals. Theophylline clearance is affected by a variety of factors, including disease states and concurrent drug therapy. The dose used should, therefore, take into account these factors, which are listed in Table 25.5. Plasma levels may be taken after 3–4 days at the higher dose, and it has been normal practice to adjust the dose to keep the plasma level within a therapeutic window of 10–20 mg/L, although improvements in respiratory function are seen at levels as low as 5 mg/L in some patients. As the bronchodilating effects of theophylline are proportional to the log of the plasma concentrations, there is proportionally less bronchodilation as the plasma level increases. The mild side effects such as nausea and vomiting are seen at concentrations as low as 13 mg/L but are more common over 20 mg/L. Significant cardiac symptoms, tachycardia and persistent vomiting are usually seen at concentrations of 40 mg/L while severe CNS effects, such as seizures, have been seen at 30 mg/L but are more common above 50 mg/L.

Table 25.5 Factors affecting theophylline clearance

Decreased clearance Increased clearance
Congestive cardiac failure Cigarette smoking
Cor pulmonale Children 1–12 years
Chronic obstructive pulmonary disease High-protein, low-carbohydrate diet
Viral pneumonia Barbecued meat
Acute pulmonary oedema Carbamazepine
Cirrhosis Phenobarbital
Premature and term babies Phenytoin
Elderly Sulfinpyrazone
Obesity  
High-carbohydrate, low-protein diet  
Cimetidine  
Erythromycin  
Oral contraceptives  
Ciprofloxacin  
Propranolol  

Differing brands of theophylline have differing bioavailabilities, so brands should not be interchanged.

Preventer medication

Anti-inflammatory agents

Regular anti-inflammatory treatment should be used for patients who are not controlled on a SABA alone (BTS/SIGN, 2009). Corticosteroids are the most commonly used anti-inflammatory agents (Table 25.6), but others such as the cromones are available.

Table 25.6 Inhaled corticosteroids used for the prophylaxis of asthma

  Total daily dosage range (MDI)
Drug and age range Standard dose High dose
Beclometasone diproprionate or budesonidea
Adult 100–400 μcg twice a day 400–1000 μcg twice a day
12–18 years 100–400 μcg twice a day 400–1000 μcg twice a day
Under 12 years 100–200 μcg twice a day 200–400 μcg twice a day
Ciclesonide
Adult 80 μcg once daily 160 μcg once daily
Fluticasone
Adult 50–200 μcg twice a day 400–1000 μcg twice a day
12–18 years 50–200 μcg twice a day 200–500 μcg twice a day
4–12 years 50–100 μcg twice a day 100–200 μcg twice a day
Mometasone
Adult 200–400 μcg once daily 400 μcg twice a day
12-18 years 200 μcg twice a day Up to 400 μcg twice a day

a There are bioavailability differences between CFC-free steroid inhalers. Always check dosing for specific brands.

Inhaled corticosteroids

Corticosteroids suppress the chronic airway inflammation associated with asthma. At present, ICSs are the initial drugs of choice, with a starting dose for an adult of beclometasone or budesonide 400 μcg/day (or an equivalent) given in divided doses.

The threshold frequency of β2-agonist use which prompts the start of ICSs has not been fully established but national guidance (BTS/SIGN, 2009) recommends considering ICS for patients with any of the following:

If symptoms persist, the ICS dose is increased stepwise accordingly. The ICS dose should be reduced, if possible, once symptoms and PEF rates have improved and stabilised. If a patient’s asthma cannot be controlled by the above ICS dose and the inhaler technique and adherence are adequate, the dose can be increased to a maximum of 1.5–2 mg a day.

All ICSs have dose-related side effects. Adrenal suppression occurs at around doses of >1500 μcg/day of beclometasone in adults. In children, doses of 400 μcg/day of beclometasone or more are associated with growth failure and adrenal suppression; children treated at these doses should be under the care of a specialist paediatrician. Oropharyngeal side effects such as candidiasis are also more common at higher doses (Box 25.2). Measures to minimise this can be tried, such as using a large-volume spacer device and rinsing the mouth with water or brushing teeth after inhalation, but there is little evidence to confirm how effective these are.

Box 25.2 Adverse reactions associated with drugs used in the management of asthma

Acute severe asthma

The management of acute asthma depends on the severity of the attack and its response to treatment, as well as an appreciation of the patient’s past history and present treatment. If an acute attack becomes persistent and difficult to treat, it is known as acute severe asthma. The aims of treatment are to prevent any deterioration in the patient’s condition and hasten recovery.

Immediate management

The immediate treatment of acute severe asthma should take place in the patient’s home if a moderate attack. Admission to hospital is considered if PEF drops below 50% predicted or normal, or the patient cannot complete sentences in one breath or is too breathless to talk, or if life-threatening features are present. A suggested treatment protocol for management in hospital is outlined in Fig. 25.5.

image

Fig. 25.5 Management of acute severe asthma in adults in hospital

reproduced by permission of the Scottish Intercollegiate Guidelines Network from BTS/SIGN, 2009.

Oxygen is administered to achieve an oxygen saturation of 92% or more. A β2-agonist is administered by metered dose inhaler (MDI) with a spacer attachment (4 puffs, then 2 puffs every 2 min until 10 mg or symptom relief) as there is no demonstrable difference between this and using a nebuliser. With more severe symptoms, or during an admission to hospital, nebulisers are used because they permit a high dose (10–20 times the dose of a MDI) and they require no co-ordination on the part of the patient between inspiration and actuation, which is helpful in those distressed. Patients undergoing an acute attack often have an inspiratory rate that is too low to use an MDI effectively.

Corticosteroids are also given in the acute attack; oral prednisolone (40–50 mg daily, for 5 days). Intravenous hydrocortisone (100 mg) should only be required if the patient cannot take oral medication. This reduces and prevents the inflammation that causes oedema and hypersecretion of mucus and hence helps to relieve the resultant smooth muscle spasm. The clinical response to both oral and parenteral steroids has an onset at 1–2 h with a peak effect at 6–8 h. If life-threatening features are present, such as cyanosis, bradycardia, confusion, exhaustion or unconsciousness, higher dose bronchodilators are used: nebulised salbutamol 5 mg with ipratropium bromide 500 μcg, repeated after 15 min; with subsequent consideration to continuous nebulisation of salbutamol at 5–10 mg/h. The addition of an anticholinergic such as ipratropium often gives a response that is greater than that of the two agents used alone.

Intravenous aminophylline can be given with a bolus dose of 250 mg over 30 min, followed by a continuous infusion of 500 μcg/kg/h. The bolus should be omitted if the patient is known to take oral theophylline or aminophylline. The choice between intravenous aminophylline and β2-agonist depends on concurrent therapy and side effect profiles. The dose of intravenous aminophylline used must also take into account recent theophylline therapy in addition to other factors (Table 25.7). Serious toxicity can occur with parenteral aminophylline and patients must be carefully monitored for nausea and vomiting, the most common early signs of toxicity. If the aminophylline infusion is continued for more than 24 h, the plasma theophylline concentration may be measured to guide any necessary alteration in infusion rate in order to maintain the level in the optimum range of 10–20 mg/L.

Table 25.7 Intravenous aminophylline dosing in acute severe asthma

  Aminophylline dose Patient characteristics
Loading dose 5 mg/kg over 20–30 min Adults and children
  3 mg/kg over 10–15 min Previous theophylline therapy (although some authorities do not use a loading dose in these patients)
Maintenance dose 500 μcg/kg/h Non-smoking adults
  700 μcg/kg/h Children under 12 or smokers
  200 μcg/kg/h Cardiac failure, liver impairment, pneumonia

Intravenous magnesium sulphate, 1.2–2 g as a 20-min infusion, has been shown to help in some patients who have not had a good response to initial treatment. There is, however, no evidence to support repeated dosing regardless of therapeutic outcome.

Further deterioration in condition may require assisted mechanical ventilation on an intensive care unit. Regular monitoring of arterial blood gases and oxygen saturation is performed to help detect any deterioration in condition.

Antibiotics are only indicated where there is evidence of a bacterial infection.

Ongoing management

The subsequent management of acute severe asthma depends on the patient’s clinical response. All patients should be monitored throughout their treatment with objective measures of their PEFs before and after bronchodilator treatment and with continual monitoring of their arterial blood gas concentrations to ensure adequate oxygen is being given.

As the patient responds to treatment, infusions can be stopped and other treatment changed or tailed off as described above. As improvement continues, an inhaled β2-agonist is substituted for the nebulised form and the oral corticosteroids stopped or reduced to a maintenance dose if clinically necessary. Throughout the treatment programme, potential drug interactions should be anticipated and managed appropriately (Table 25.8).

Table 25.8 Common clinically significant interactions with drugs used in the management of asthma

Drug Interacting drug Probable mechanism and clinical result
β2-Agonists Methyldopa Acute hypotension possible with β2-agonist infusions
Corticosteroids Anticoagulants High-dose steroids enhance anticoagulant effect of coumarins
  Antifungals Metabolism of steroids possibly affected by antifungal agents
  Barbiturates Accelerates steroid metabolism
  β2-Agonists Increased risk of hypokalaemia with high doses
  Carbamazepine Reduced steroid effect due to increased metabolism
  Ciclosporin Increases plasma concentration of prednisolone
  Methotrexate Increased risk of haematological toxicity
  Phenytoin Reduced steroid effect due to increased metabolism
  Rifampicin Reduced steroid effect due to increased metabolism
Theophylline Azithromycin May increase theophylline plasma levels
  β2-Agonists (high dose) Increased risk of hypokalaemia
  Carbamazepine Induction of theophylline metabolism resulting in decreased plasma levels
  Clarithromycin Inhibition of theophylline metabolism resulting in increased plasma levels
  Cimetidine Inhibition of theophylline metabolism resulting in increased plasma levels
  Ciprofloxacin Increased plasma concentration. Possible risk of convulsions
  Diltiazem Increased theophylline plasma levels
  Erythromycin (oral) Inhibition of theophylline metabolism resulting in increased plasma levels
  Fluconazole Possible increase in theophylline plasma level
  Dihydropyridine  
  calcium antagonists May increase theophylline plasma levels
  Fluvoxamine Increased theophylline plasma levels, halve theophylline dose
  Isoniazid May increase theophylline plasma levels
  Ketoconazole Possible increase in theophylline plasma level
  Lithium carbonate Reducing plasma lithium concentrations as theophylline enhances lithium renal clearance
  Norfloxacin Increased plasma concentration. Possible risk of convulsions
  Phenytoin Plasma concentrations of theophylline and phenytoin both reduced
  Primidone Induction of theophylline metabolism resulting in decreased plasma levels
  Rifampicin Induction of theophylline metabolism resulting in decreased plasma levels
  Ritonavir Metabolism of theophylline increased
  Smoking (tobacco) Induction of theophylline metabolism resulting in decreased plasma levels
  St John’s wort Reduced theophylline plasma levels
  Verapamil Increased theophylline plasma levels

All patients should have a follow-up after an acute attack with symptoms monitored, reasons for admission addressed and inhaler technique checked. A self-management plan should be drawn up and discussed with each patient.

Patient care

The correct use of drugs and the education of patients are the cornerstones of asthma management. There are three main steps in the education of the asthmatic patient.

All members of the health care team should provide education and support for the asthmatic patient at regular intervals. The need for each patient to understand their asthma and its management must be balanced against the dangers of overwhelming the patient with information, particularly when the asthma has been newly diagnosed. To try to overcome this, a ‘ladder of asthma knowledge’ has been proposed. Patients are counseled in a gradual manner, each session adding to the previous one in content and reinforcing existing knowledge (Box 25.3).

Inhalation device

The choice of a suitable inhalation device is vital in asthma management. The incorrect use of inhalers will lead to suboptimal treatment. A review of inhaler technique studies has concluded that up to 50% of patients in Europe are unable to use their inhaler correctly (Crompton et al., 2006). There is no demonstrable difference in efficacy between the various devices available. Other factors, therefore, need to be considered when choosing the appropriate device, including the patient’s age, severity of disease, manual dexterity, co-ordination and personal preference. The range of different devices available for the drugs commonly used in asthma is shown in Table 25.9.

Metered dose aerosol inhalers

The pressurised MDI is the most widely prescribed inhalation device in the UK (Fig. 25.6). It usually contains a solution or suspension of active drug, with a typical particle size of 2–5 μm, in a liquefied propellant. Operation of the device releases a metered dose of the drug with a droplet size of 35–45 μm. The increased droplet size is due to the propellant, which evaporates when expelled from the inhaler. Inhalers have now been switched from chlorofluorocarbon (CFC) propellants to newer, non-CFC, hydrofluoroalkanes.

MDIs have the advantage of being multidose, small and widely available for most drugs used in asthma management. Their main disadvantage is that correct use requires a good technique. A particular problem for many patients is co-ordinating the beginning of inspiration with the actuation of the inhaler. Even when this is done correctly, MDIs only deliver about 10% of drug to the airways, with 80% deposited in the oropharynx. Corticosteroids administered by MDIs can cause dysphonia and oral candidiasis. The candidiasis can be minimised either by advising patients to gargle with water after using the inhaler and to expel the water from the mouth afterwards, or by using a spacer device. Newer devices are utilising other mechanisms to produce an aerosol such as a soft mist inhaler (SMI) which may give benefits in lung deposition and ease of use.

Younger children, in particular, find MDIs difficult to use and the addition of a spacer device can make this easier, allowing inhalation over several ambient breaths.

The correct technique for using MDIs is as follows:

Studies indicate that personal tuition improves inhaler technique, particularly if regularly repeated. Other methods of instruction include videos (see http://medguides.medicines.org.uk/demonstrations.aspx), package inserts and information leaflets or booklets provided by organisations such as Asthma UK and the pharmaceutical industry. Regular patient review, at least annually, is recommended. This can be used as an opportunity to check technique, along with assessment of the ability to generate the appropriate inspiratory flow for the device (Broeders et al., 2009).

Metered dose inhaler with a spacer extension

Extension devices allow greater evaporation of the propellant, so reducing particle size and velocity. This also reduces oropharyngeal deposition and potentially increases lung deposition. Oral candidiasis and dysphonia (impaired voice) from ICSs may also be reduced by using these devices. Spacers are useful for people who have poor co-ordination between inspiration and actuation and several types of spacer are available. In younger children, these offer advantages over MDIs alone with respect to adherence. Recommendations (see Table 25.10) have been published regarding device choice (NICE, 2000, 2002).

Large-volume (750 mL) spacers are available such as the Volumatic® (Fig. 25.7); these are manufacturer specific and have not been assessed or licensed for use with devices of other companies. These spacers have one-way valves that allow several inhalations of one dose from the spacer’s chamber. No co-ordination is required between actuation of the MDI and inhalation. A large-volume spacer can be used instead of a nebuliser to deliver high doses of a β2-agonist in acute severe asthma attacks. Disadvantages of these spacers include their large size, which renders them less portable, and their proven efficacy only with inhalers from the same manufacturer. Spacers should be washed regularly in warm, soapy water and left to drip dry without rinsing. Cloths should not be used for drying a spacer as this affects the antistatic coating of plastic spacers. All spacers should be replaced every 6–12 months. Facemasks are available for young children.

Small- and medium-volume spacer devices are available, either as an integral part of the design of some MDIs or as a separate device (Fig. 25.8). These spacers have also been used to compensate for poor inhaler technique in adults and reduce the oropharyngeal deposition of steroids. These are more convenient to carry around than the larger spacers. The published evidence of additional benefit from these devices in either increasing efficacy or decreasing adverse effects is more limited than with large volume spacers.

Dry powder inhalers

Several types of dry powder inhalers (DPIs) are available. These are propellant free and are designed to be easier to use than conventional MDIs. They are useful for those who have difficulty co-ordinating an MDI and can be used by children as young as 4 years old. Table 25.10 sets out the recommendations for device choice in children.

DPIs are available as either single-dose or multiple-dose devices (Fig. 25.10). Single-dose devices pierce or break a gelatin capsule to release the contents and must be regularly cleaned to avoid powder clogging the device. Multiple-dose devices are preferred by many patients since they avoid having to reload for each dose. Care must be taken to hold these devices in the correct orientation to avoid the powder falling out of the device before inhalation. Patients commenced on DPIs are sometimes concerned at the absence of any taste or spray plume which they have become accustomed to when using an MDI; reassurance that this is perfectly normal and that correct use of the DPI (including a check that the device is not empty) will ensure that the required dose is delivered should overcome this problem.

Nebulisers

A nebuliser produces an aerosol by blowing air or oxygen through a solution to produce droplets of 5 μm or less in size. Nebulisers require little co-ordination from the patient as any drug is inhaled through a facemask or mouthpiece using normal tidal breathing. Only about 13% of the dose used is deposited in the lungs, but because the doses used are higher than those used in other aerosol devices, patients will generally receive a higher dose than from an MDI. However, in mild and moderate exacerbations of asthma, no benefit has been shown over using 4–6 puffs of a MDI.

Nebulisers are useful in patients who are unable to use conventional inhalers, for example, children under 2 years old, patients with severe attacks of asthma unable to produce sufficient inspiratory effort and those lacking the co-ordination to use other inhalers. Nebulised bronchodilators can be used in acute severe asthma attacks, often avoiding the need for intravenous drugs.

Most of the short-acting β2-agonists, as well as ipratropium bromide, fluticasone, budesonide and sodium cromoglicate, are available for nebulisation.

The safe and correct use of nebulisers requires careful counselling, especially if they are to be used in the home. The following points are critical for the correct use of a nebuliser.

There are disadvantages with the use of nebulisers. Of particular concern is the overreliance on the nebuliser by some patients which results in a delay in seeking medical advice. The high doses of bronchodilators used can also increase the incidence of side effects, and these vary depending on the drug nebulised.

Self-management programmes

Every individual with asthma should be considered for a self-management education programme. These programmes will contain structured education along with an individualised action plan. They aim to give the individual more confidence by involving them in the management of their own asthma. The individual should then be able to deal with any fluctuation in their condition and know when to seek medical advice. Personalised action plans have been shown to improve health outcomes in individuals with asthma (Gibson et al., 2002).

Key elements of an action plan include being able to monitor symptoms, measure peak flow, understand their medicine and how it should be used, and knowing how to deal with fluctuations in severity of asthma according to written guidance. Symptom diaries, management guidance cards and peak flow reading diary cards are available from organisations such as Asthma UK and pharmaceutical companies who manufacture asthma products.

An action plan can also include details of when to increase the dose of an inhaled steroid, when to take a short course of oral corticosteroids and when to self-refer to a general medical practitioner or local hospital (Table 25.11).

Table 25.11 Example of a personalised action plan setting out the action required in response to a given peak flow reading and/or symptoms

Peak flow Example of symptoms Action
>80% of personal best value Intermittent or few symptoms When required, β2-agonist for symptom relief, continue regular inhaler corticosteroid, consider reducing the dosage every 3 months if stable
61–80% of best Waking at night Double dose of inhaled corticosteroid if taking <400 μcg day BDP
  Symptoms of a cold
    Start oral corticosteroid if taking >400 μcg/day BDP
40–60% of best Increasing breathlessness or using a β2-agonist every 2–3 h Start oral corticosteroid course. Contact a doctor
<40% of best Severe attack Call emergency doctor or ambulance urgently
Poor response to β2-agonist

BDP, equivalent dose of beclometasone dipropionate.

Case studies

Answers

Answers

Practical information and treatment plans should be reinforced with written instruction; this can also be from patient support groups such as Asthma UK http://www.asthma.org.uk/. Every subsequent consultation with any health care professional should be an opportunity to review reinforce and extend both knowledge and skills.

2. There is no doubt that increased allergen exposure in sensitised individuals is associated with an increase in asthma symptoms, bronchial hyperresponsiveness and deterioration in lung function (BTS/SIGN, 2009); this includes animal allergens. However, the removal of cats from the home has not been shown to always benefit individuals with asthma. The reduction of exposure to other allergens, such as house dust mite, may also be considered for their potential effect on asthma symptoms. There is no evidence for the effectiveness of dust mite reduction strategies (Getzsche and Johansen, 2008).

If these measures provide no benefit to asthma symptoms or quality of life after a trial of a few months, they should be stopped.

Answers

References

Asthma UK. Out in the open. A true picture of asthma in the United Kingdom today, National Asthma Campaign asthma audit 2001. Asthma J., 6. 2001: 1-14.

British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). Update: British guideline on the management of asthma. Available at http://www.sign.ac.uk/guidelines/fulltext/101/index.html, 2009.

Broeders M., Sanchis J., Levy M., et al. The ADMIT series – Issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Primary Care Respir. J.. 2009;18:76-82. Available at http://www.thepcrj.org/journ/view_article.php?article_id=627

Crompton G.K., Barnes P.J., Broeders M., et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir. Med. 2006;100:1479-1494.

Douwes J., Gibson P., Pekkanen J., et al. Non-eosiniphilic asthma: importance and possible mechanisms. Thorax. 2002;57:643-648.

Getzsche P.C., Johansen H.K. House dust mite control measures from asthma. Cochrane Database of Systematic Reviews. 2008. Issue 2 Art No. CD001187. doi:10.1002/14651858. CD001187

Gibson P.G., Powell H., Wilson A., et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews. 2002. Issue 3. Art. No. CD001117. doi:10.1002/14651858. CD001117

GINA Global Initiative for Asthma. Global strategy for asthma management and prevention. GINA. 2009. Available at http://www.ginasthma.com/GuidelinesResources.asp?l1=2&l2=0

Holgate S., Arshad H.S., Roberts G.C., et al. A new look at the pathogenesis of asthma. Clin. Sci.. 2010;118:439-450.

Medicines and Healthcare products Regulatory Agency. Asthma: Long-Acting β2-Agonists. London: MHRA, 2008. Available at http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Asthma/index.htm

National Institute for Health and Clinical Excellence. Guidance on the Use of Inhaler Systems (Devices) in Children Under 5 Years with Chronic Asthma. London: NICE, 2000. Technology Appraisal 10. Available at http://guidance.nice.org.uk/TA10

National Institute for Health and Clinical Excellence. Inhaler Devices for Routine Treatment of Chronic Asthma in Older Children (Aged 5–15 Years). London: NICE, 2002. Technology Appraisal 38. Available at http://guidance.nice.org.uk/TA38

National Institute for Health and Clinical Excellence. Omalizumab for Severe Persistent Allergic Asthma. London: NICE, 2007. Technology Appraisal 133. Available at http://guidance.nice.org.uk/TA133

National Prescribing Centre (NPC). Current issues in the Drug Treatment of Asthma. MeReC Bull.. 2008;19:1-6. Available at http://www.npc.co.uk/ebt/merec/resp/asthma/merec_bulletin_vol19_no2.html

Saltpeter S.R., Buckley N.S., Ormiston T.M., et al. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann. Intern. Med.. 2006;144:904-912.